Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 receptor expression by immuno-PET
G Vaidyanathan, D McDougald, J Choi… - Journal of Nuclear …, 2016 - Soc Nuclear Med
The human growth factor receptor type 2 (HER2) is overexpressed in breast as well as other
types of cancer. Immuno-PET, a noninvasive imaging procedure that could assess HER2 …
types of cancer. Immuno-PET, a noninvasive imaging procedure that could assess HER2 …
Fluorine-18 labeling of the HER2-targeting single-domain antibody 2Rs15d using a residualizing label and preclinical evaluation
Z Zhou, G Vaidyanathan, D McDougald… - Molecular Imaging and …, 2017 - Springer
Purpose Our previous studies with F-18-labeled anti-HER2 single-domain antibodies (sdAbs)
utilized 5F7, which binds to the same epitope on HER2 as trastuzumab, complicating its …
utilized 5F7, which binds to the same epitope on HER2 as trastuzumab, complicating its …
[HTML][HTML] Evaluation of an 131I-labeled HER2-specific single domain antibody fragment for the radiopharmaceutical therapy of HER2-expressing cancers
Y Feng, R Meshaw, D McDougald, Z Zhou, XG Zhao… - Scientific Reports, 2022 - nature.com
Radiopharmaceutical therapy (RPT) is an attractive strategy for treatment of disseminated
cancers including those overexpressing the HER2 receptor including breast, ovarian and …
cancers including those overexpressing the HER2 receptor including breast, ovarian and …
Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases
…, RC Crumrine, MA Leenitzer, DL McDougald… - … of Pharmacology and …, 2001 - ASPET
Tumor necrosis factor-α (TNF)-converting enzyme (TACE) cleaves the precursor form of TNF,
allowing the mature form to be secreted into the extracellular space. GW3333, a dual …
allowing the mature form to be secreted into the extracellular space. GW3333, a dual …
Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE)
…, MA Leesnitzer, DL McDougald… - Journal of Medicinal …, 2001 - ACS Publications
A program to improve upon the in vitro, in vivo, and physicochemical properties of N-hydroxyformamide
TACE inhibitor GW 3333 (1) is described. Using the primary structure of pro-TNF-…
TACE inhibitor GW 3333 (1) is described. Using the primary structure of pro-TNF-…
Structure-based design of potent retinoid X receptor α agonists
…, JM Lenhard, AB Miller, DL McDougald… - Journal of medicinal …, 2004 - ACS Publications
A series of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids that showed
potent agonist activity against RXRα were synthesized via a structure-based design …
potent agonist activity against RXRα were synthesized via a structure-based design …
Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors
G Vaidyanathan, CM Kang, D McDougald… - Nuclear medicine and …, 2018 - Elsevier
Introduction Radiolabeled, low-molecular-weight prostate-specific membrane antigen (PSMA)
inhibitors based on the Glu-ureido pharmacophore show promise for the detection and …
inhibitors based on the Glu-ureido pharmacophore show promise for the detection and …
Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent
Y Feng, Z Zhou, D McDougald, RL Meshaw… - Nuclear medicine and …, 2021 - Elsevier
Introduction As a consequence of their small size, high stability and high affinity, single
domain antibody fragments (sdAbs) are appealing targeting vectors for radiopharmaceutical …
domain antibody fragments (sdAbs) are appealing targeting vectors for radiopharmaceutical …
Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[18F]Fluoronicotinate Resulting in High Tumor-to-Kidney Ratios
Z Zhou, D McDougald, N Devoogdt… - Molecular …, 2018 - ACS Publications
ImmunoPET agents are being investigated to assess the status of epidermal growth factor
receptor 2 (HER2) in breast cancer patients with the goal of selecting those likely to benefit …
receptor 2 (HER2) in breast cancer patients with the goal of selecting those likely to benefit …
N-Succinimidyl 3-((4-(4-[18 F] fluorobutyl)-1 H-1, 2, 3-triazol-1-yl) methyl)-5-(guanidinomethyl) benzoate ([18 F] SFBTMGMB): a residualizing label for 18 F-labeling of …
G Vaidyanathan, D McDougald, J Choi… - Organic & …, 2016 - pubs.rsc.org
Residualizing labeling methods for internalizing peptides and proteins are designed to trap
the radionuclide inside the cell after intracellular degradation of the biomolecule. The goal of …
the radionuclide inside the cell after intracellular degradation of the biomolecule. The goal of …